test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works
       

Advanced Search
Home   
 
Browse   
Communities
& Collections
  
Issue Date   
Author   
Title   
Subject   
 
Sign on to:   
Receive email
updates
  
My Account
authorized users
  
Edit Profile   
 
Help   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/24117


Title: Symposium - Recent Understanding in the Treatment of Visceral Leishmaniasis
Authors: Rosenthal, E.
Marty, P.
Keywords: Drug resistance; HIV; developing countries; liposomal amphotericin B; amphotericin B; pentavalent antimonials; miltefosine
Issue Date: 31-Dec-2003
Publisher: Medknow Publications and Staff Society of Seth GS Medical College and KEM Hospital, Mumbai, India
Citation: Journal of Postgraduate Medicine (ISSN: 0972-2823) Vol 49 Num 1
Abstract: Visceral leishmaniasis (VL) is a severe disease associated with infection of the reticuloendothelial system by Leishmania species. The infection is acquired through sandfly bites. Recent large scale epidemics of VL in east Africa and India and the emergence of a HIV epidemic make VL a priority for the World Health Organization. Pentavalent antimonials have been cornerstone of treatment for the last six decades. The appearance of antimonial-resistance and the development of lipid formulations of amphotericin B have changed the pattern of VL treatment. Within the past five years, miltefosine has been demonstrated as the first effective and safe oral treatment against VL. The price of miltefosine is yet to be determined. However, miltefosine will certainly be cheaper than lipid formulations of amphotericin B, which are beyond the financial capacity of the poor countries. Because it can be administered orally, miltefosine is suited for the treatment of large number of patients who get affected during epidemics, particularly in regions where the parasites are resistant to the currently used agents. Here, we recommend different treatment schedules according to the resistance pattern and the region-specific socio-economical and cultural factors. (J Postgrad Med 2003;49:61-68)
URI: http://hdl.handle.net/1807/24117
Other Identifiers: http://www.bioline.org.br/abstract?id=jp03012
Rights: Copyright 2003 - Journal of Postgraduate Medicine. Online full text also at http://www.jpgmonline.com
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
jp03012.html47.29 kBHTMLView/Open

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

uoft